Abstract: A lithium-ion secondary battery where a current collecting member and a foil are joined to each other securely while damage of the foil is suppressed is provided. The lithium-ion secondary battery is provided with a winding group obtained by winding a positive electrode plate and a negative electrode plate via a separator. An end portion of a positive electrode mixture non-application portion and an end portion of a negative electrode mixture non-application portion project at an upper portion and a lower portion of the winding group, respectively. Current collecting disks 7 are disposed so as to face both end faces of the winding group, respectively. The current collecting disk 7 has projecting ridge portions 8 on a face thereof opposite to the winding group and flat face portions facing the winding group at positions corresponding to the projecting ridge portions 8. The projecting ridge portions 8 are formed radially.

Abstract: A battery box housing a battery is mounted between left and right side frames extending in a longitudinal direction of a vehicle body so that the battery box is offset to a left side of the vehicle body, and an intake duct and an exhaust duct for cooling air for cooling the battery are connected to an end of the battery box on a right side of the vehicle body. Therefore, it is possible not only to protect the battery between the left and right frames from a shock caused upon a side collision, but also to ensure a space for disposition of the intake duct and the exhaust duct while ensuring a volume of the battery box to the maximum. Moreover, the battery box is connected at its left and right ends to the left and right side frames.

Abstract: A production method, comprising a step of synthesizing silicon particle-containing silicon oxide particles by performing a gas phase reaction of monosilane gas and oxidizing gas for oxidizing the monosilane gas and a step of removing the silicon oxide with hydrofluoric acid after holding the silicon oxide particle powder in an inert atmosphere at 800-1400?, provides high-purity silicon nanoparticles which are highly practical as material powder for high-performance light-emitting elements and electronic parts in an industrial scale.

Abstract: The present invention is directed to a compound represented by formula (1): (wherein R1 represents an alkyl group which may have a substituent or an alkenyl group which may have a substituent; and each of R2 and R3 represents a hydrogen atom, an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group, or an alkynyl group, or R2 and R3 form, together with the nitrogen atom adjacent thereto, a nitrogen-containing saturated heterocyclic group which may have a substituent) and a drug composition containing the compound. The compound exhibits tumor necrosis factor (TNF-?) production inhibitory effect and improved absorption upon oral administration.

Abstract: The battery box structure of the present invention includes: a plurality of battery modules; a pair of holding frames which hold the battery modules; and an insulator which is made from expanded insulating resin and which stores the holding frame.

Abstract: A voltage detection terminal mounted to a housing plate body includes a bus bar connecting portion (4a) which is connected to a battery electrode and a bus bar (3) by bolt-nut connection, a detector connecting portion (4b) connected to voltage detector, and an interconnecting portion (4c) interconnecting the bus bar connecting portion and the detector connecting portion. A gap (c) for absorbing a length variation of a battery cell is formed between the plate body and the bus bar connecting portion, and the interconnecting portion (4c) includes a slanting portion (4c) for preventing the interconnecting portion from interference with the bus bar is formed at part of the interconnecting portion.

Abstract: A phenylpyridazine derivative represented by the formula (1): Wherein, R1, R2, R3, X, Y, Z and n have the same meaning as defined in the specification; or a salt thereof, or a medicine containing the compound. The present invention provides water-soluble phenylpyridazine derivatives and medicines containing them, which have excellent inhibitory activity against interleukin-? production, high water solubility and high oral absorbability.

Abstract: A bis(5-aryl-2-pyridyl) compound represented by formula (1) or a salt thereof: wherein A is a substituted or unsubstituted aromatic hydrocarbyl group or a substituted or unsubstituted aromatic heterocyclic group, and X is a group selected from the group consisting of moieties having formulas (2) to (5): wherein, in formula (2), m is an integer of 1 or 2; in formula (3), n is an integer of 1 to 6; and in formula (4), R is hydrogen or a lower alkyl group and p is an integer of 1 to 6.

Abstract: The present invention is directed to a compound represented by formula (1): (wherein R1 represents an alkyl group which may have a substituent or an alkenyl group which may have a substituent; and each of R2 and R3 represents a hydrogen atom, an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group, or an alkynyl group, or R2 and R3 form, together with the nitrogen atom adjacent thereto, a nitrogen-containing saturated heterocyclic group which may have a substituent) and a drug composition containing the compound. The compound exhibits tumor necrosis factor (TNF-?) production inhibitory effect and improved absorption upon oral administration.

Abstract: A voltage detection terminal includes a bus bar connecting portion which is connected to a battery electrode and a bus bar by bolt-nut connection, a detector connecting portion connected to voltage detector, and an interconnecting portion interconnecting the bus bar connecting portion and the detector connecting portion. A gap for absorbing a length variation of a battery cell is formed between a plate body and the bus bar connecting portion, and a slanting portion for preventing the interconnecting portion from interference with the bus bar is formed at part of the interconnecting portion.

Abstract: Compounds having the formula (1): wherein R1 represents an alkyl or alkenyl group, R2 and R3 each independently represent a hydrogen atom or an alkyl, hydroxyalkyl, dihydroxyalkyl or alkynyl group, or R2 and R3 may be fused together with the adjacent nitrogen atom to form a substituted or unsubstituted, nitrogen-containing, saturated heterocyclic group, X, Y and Z each independently represent a hydrogen atom, an alkyl group, a halogen atom or the like, and n stands for an integer of from 1 to 5; and also to medicinal compositions containing them. These compounds have inhibitory activity against IL-1? production, high water solubility and good oral absorbability.

Abstract: A phenylpyridazine derivative represented by the formula (1): Wherein, R1, R2, R3, X, Y, Z and n have the same meaning as defined in the specification; or a salt thereof, or a medicine containing the compound. The present invention provides water-soluble phenylpyridazine derivatives and medicines containing them, which have excellent inhibitory activity against interleukin-? production, high water solubility and high oral absorbability.

Abstract: In order to reduce the number of processes for manufacturing spacers and to prevent quality degradation resulting from a cell gap, a spacer 115 in a semi-transmission area 12 is formed outside of a region of a bump layer 118B. Thus, it is made possible to manufacture the spacer in the transmission region 11 and the spacer outside of the region of the bump layer in the same process. Accordingly, the number of processes can be reduced. Moreover, it is made possible to determine the cell gap in the semi-transmission area 12 by a single element of a spacer. Accordingly, precision degradation of the cell gap, which results from the bump layer, can be prevented, and high display quality can be obtained.

Abstract: A bis(5-aryl-2-pyridyl) compound represented by formula (1) or a salt thereof: wherein A is a substituted or unsubstituted aromatic hydrocarbyl group or a substituted or unsubstituted aromatic heterocyclic group, and X is a group selected from the group consisting of moieties having formulas (2) to (5): wherein, in formula (2), m is an integer of 1 or 2; in formula (3), n is an integer of 1 to 6; and in formula (4), R is hydrogen or a lower alkyl group and p is an integer of 1 to 6.

Abstract: A bis(2-aryl-5-pyridyl) compound having formula (1) or a salt thereof: wherein A is a substituted or unsubstituted aromatic hydrocarbon group, and X is a substituent having one of the following formulas (2) to (4): wherein, in formula (2), R1 is a hydrogen atom or a di(lower alkyl)amino(lower alkyl) group, and m is an integer of 1 or 2; in formula (3), Y1 and Y2 each is a nitrogen atom or a CH group, and n is 0 or an integer of 1 to 6; in formula (4), R2 and R3 each is a hydrogen atom or a lower alkyl group, Z represents a single bond, a substituted methylene group, a substituted imino group, an oxygen atom or a cycloalkylene group, and p and q each is 0 or an integer of 1 to 6.

Abstract: A liquid crystal display device includes a thin film transistor (TFT) array substrate 10, a counter substrate 22 provided opposite to the TFT array substrate 10 and a liquid crystal layer 28 held between the TFT array and counter substrates 10 and 22. The TFT array substrate 10 has display and frame areas 31 and 32. There are pixel electrodes in the display area 31 which each have reflective and transparent portions 33 and 34 with convex and concave portions 29 and 30, respectively. Convex and concave portions 36 and 37 are also provided in the frame area 32 which are substantially the same in shape as convex and concave portions 29 and 30 in the display area 31. The surface of a photoresist coating film in the display area 31 shown by a dotted line 39 is substantially the same in configuration as that in the frame area 32 to make the column-like spacers 27 and 38 substantially the same in height. A cell gap between the TFT array and counter substrates 10 and 22 is made thereby substantially uniform.

Abstract: Compounds having the formula (1): wherein R1 represents an alkyl or alkenyl group, R2 and R3 each independently represent a hydrogen atom or an alkyl, hydroxyalkyl, dihydroxyalkyl or alkynyl group, or R2 and R3 may be fused together with the adjacent nitrogen atom to form a substituted or unsubstituted, nitrogen-containing, saturated heterocyclic group, X, Y and Z each independently represent a hydrogen atom, an alkyl group, a halogen atom or the like, and n stands for an integer of from 1 to 5; and also to medicinal compositions containing them. These compounds have inhibitory activity against IL-1? production, high water solubility and good oral absorbability.

Abstract: Compounds having the formula (1): wherein R1 represents an alkyl or alkenyl group, R2 and R3 each independently represent a hydrogen atom or an alkyl, hydroxyalkyl, dihydroxyalkyl or alkynyl group, or R2 and R3 may be fused together with the adjacent nitrogen atom to form a substituted or unsubstituted, nitrogen-containing, saturated heterocyclic group, X, Y and Z each independently represent a hydrogen atom, an alkyl group, a halogen atom or the like, and n stands for an integer of from 1 to 5; and also to medicinal compositions containing them. These compounds have inhibitory activity against IL-1? production, high water solubility and good oral absorbability.

Abstract: Compounds having the formula (1): wherein R1 represents an alkyl or alkenyl group, R2 and R3 each independently represents a hydrogen atom or an alkyl, hydroxyalkyl, dihydroxyalkyl or alkynyl group, or R2 and R3 may be fused together with the adjacent nitrogen atom to form a substituted or unsubstituted, nitrogen-containing, saturated heterocyclic group, X, Y and Z each independently represents a hydrogen atom, an alkyl group, a halogen atom or the like, and n stands for an integer of from 1 to 5; and also to pharmaceutical compositions containing them. These compounds have inhibitory activity against IL-1? production, high water solubility and good oral absorbability.